PMC:7299399 / 29992-30592
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T126 | 51-62 | Body_part | denotes | interleukin | http://purl.org/sig/ont/fma/fma86578 |
| T127 | 64-66 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
| T128 | 204-206 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
| T129 | 231-233 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
| T130 | 245-253 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
| T131 | 273-275 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
| T132 | 324-332 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
| T133 | 526-530 | Body_part | denotes | body | http://purl.org/sig/ont/fma/fma256135 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T116 | 440-449 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T279 | 70-73 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T280 | 163-170 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
| T281 | 307-308 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T219 | 64-66 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T221 | 171-176 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T222 | 204-206 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T224 | 231-233 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T226 | 273-275 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T38 | 382-397 | http://purl.obolibrary.org/obo/GO_0045087 | denotes | innate immunity |
| T39 | 487-502 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune response |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T117 | 135-298 | Sentence | denotes | Ongoing clinical trials are testing drugs that block the receptor of IL-6 (Tocilizumab, an anti-IL-6 receptor antibody, and Sarilumab) or IL-6 itself (Siltuximab). |
| T118 | 299-531 | Sentence | denotes | Whereas a well-regulated cytokine response that is rapidly triggered by the host’s innate immunity can serve to prevent and to counteract an infection, an excessive, unbalanced, prolonged immune response can seriously harm the body. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 464 | 51-69 | Gene | denotes | interleukin (IL)-6 | Gene:3569 |
| 465 | 204-208 | Gene | denotes | IL-6 | Gene:3569 |
| 466 | 231-235 | Gene | denotes | IL-6 | Gene:3569 |
| 467 | 273-277 | Gene | denotes | IL-6 | Gene:3569 |
| 469 | 12-20 | Species | denotes | patients | Tax:9606 |
| 470 | 94-102 | Species | denotes | patients | Tax:9606 |
| 471 | 210-221 | Chemical | denotes | Tocilizumab | MESH:C502936 |
| 472 | 259-268 | Chemical | denotes | Sarilumab | MESH:C000592401 |
| 473 | 286-296 | Chemical | denotes | Siltuximab | MESH:C504234 |
| 481 | 440-449 | Disease | denotes | infection | MESH:D007239 |